Use of computed tomographic pulmonary angiography for the diagnosis of pulmonary embolism; are we overdoing it?

J Ayub Med Coll Abbottabad. 2014 Jan-Mar;26(1):76-9.

Abstract

Background: Computed tomographic pulmonary angiography (CTPA) is a gold standard test for the diagnosis of pulmonary embolism (PE), but is reported to be over prescribed. We performed this study to determine over prescription of CTPAs at a District General Hospital (DGH) in the United Kingdom. Our secondary aim was to establish a cause of its over-prescription.

Methods: We retrospectively reviewed clinical data of all patients who underwent CTPAs during January 2011 to July 2013. Collected data included CTPA findings, clinical probability score, D-dimer results, chest x-ray (CXR) findings and patient's demographic data. A calculation of overall clinical probability (including initial and post CTPA values) and its cross analysis with D-dimer, CTPA and CXR findings was made.

Results: Pulmonary embolism was positive in 5 (11.6%) cases. An Initial probability score was available in 16 (37.20%), and a D-dimer result was available in 33 (76.7%). Chest X-ray (CXR) was abnormal in 8 (18.6%). A coupling of total probability score with D-dimer results (CPPD) identified 10 (22.2%) potential over prescriptions. A further analysis of CPPD with CXR revealed a definite over prescription of 8 (18.6%), whereas it increased the number of an overall possible over prescription to 14 (32.6%).

Conclusion: The CTPAs are being over prescribed and the main reasons behind it are poor utilization of probability scoring systems, D-dimer rule and lack of interpretation of alternative diagnosis on CXRs.

MeSH terms

  • Adult
  • Aged
  • Angiography / methods
  • Angiography / statistics & numerical data*
  • Female
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Embolism / diagnostic imaging*
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods
  • Tomography, X-Ray Computed / statistics & numerical data*
  • United Kingdom

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D